Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q1 2020 · 10-Q
Revenue$1.65M$1.65M+11.6% vs Q1 2019 Net Income-$1.38M-$1.38MN/M vs Q1 2019 EPS Diluted-$0.03-$0.03N/M vs Q1 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flow-$2,872,000N/M Free Cash Flowderived-$4,045,000N/M Margins · derivedGross margin2.5%−0.4 pt vs Q1 2019
Operating margin-88.2%−53.7 pt vs Q1 2019
Net margin-83.6%−49.0 pt vs Q1 2019
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end